NASDAQ:EWTX Edgewise Therapeutics Q3 2026 Earnings Report $37.49 -2.08 (-5.27%) As of 12:30 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Edgewise Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.53Beat/MissN/AOne Year Ago EPSN/AEdgewise Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$129.17 millionBeat/MissN/AYoY Revenue GrowthN/AEdgewise Therapeutics Announcement DetailsQuarterQ3 2026Date11/5/2026TimeBefore Market OpensConference Call DateThursday, November 5, 2026Conference Call Time9:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Edgewise Therapeutics Earnings HeadlinesEdgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-154004 hours ago | prnewswire.comEdgewise Therapeutics (EWTX) Sets EDG 7500 Focus Call, Is It Still 20% Below Fair Value?October 2, 2026 | finance.yahoo.comA dividend every week of the yearMost dividend stocks pay quarterly, leaving long stretches of silence between paydays. For investors covering real expenses, that rhythm rarely lines up with the bills. Nathan Slaughter, Chief Investment Strategist at High-Yield Investing, built a full 52-week calendar by sequencing quality dividend payers so every week is covered, including bonus dividends that cluster from December through February.October 8 at 1:00 AM | Market Savvy (Ad)Edgewise Therapeutics (NASDAQ:EWTX) Shares Climb 5.9% - Still a Buy?October 2, 2026 | americanbankingnews.comEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesOctober 1, 2026 | prnewswire.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock Has Consensus Target Price of $51.33September 28, 2026 | americanbankingnews.comSee More Edgewise Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Edgewise Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edgewise Therapeutics and other key companies, straight to your email. Email Address About Edgewise TherapeuticsEdgewise Therapeutics (NASDAQ:EWTX) is a biopharmaceutical company focused on developing small-molecule therapies for severe neuromuscular and cardiovascular diseases. The company’s research is centered on muscle biology, with the goal of developing treatments that address the underlying mechanisms of muscle damage and dysfunction. Edgewise’s lead investigational product is sevasemten, formerly known as EDG-5506, a selective fast skeletal muscle myosin inhibitor being developed for dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. The company is also developing EDG-7500, an investigational cardiac myosin modulator intended for the treatment of hypertrophic cardiomyopathy and other cardiovascular conditions. Founded in 2017 and headquartered in Boulder, Colorado, Edgewise conducts research and clinical development activities through collaborations and clinical trials in the United States and other regions. Kevin Koch serves as the company’s president and chief executive officer.View Edgewise Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Skydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand ExplodesDoes Lemonade’s Growth Signal Profits Ahead?Wall Street Is Betting These 3 Beaten-Down Stocks Have More Room to Run Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
